Based on targeted product profile assessments, physicians project notable uptake following approval, with use concentrated among DM patients in need of durable, steroid-sparing efficacy. Beyond ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best stocks to buy under $20. On September 17, Roivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study, a 52-week ...

Dermatomyositis (DM) is a chronic autoimmune disease characterized by inflammatory myopathy and distinctive skin manifestations, significantly affecting patients' quality of life. Dazukibart, a novel ...

Matthew Herper covers medical innovation — both its promise and its perils. The biotech firm Roivant and its spinout Priovant said Wednesday that their immune-modifying drug brepocitinib outperformed ...

Please provide your email address to receive an email when new articles are posted on . The study included patients with cutaneous dermatomyositis and those with muscle involvement. Treatment-emergent ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Shares of Roivant Sciences (NASDAQ:ROIV) climbed 9% after the company, together with partner Priovant Therapeutics, reported encouraging Phase 3 results for brepocitinib in patients with ...

NEW ORLEANS — A monoclonal antibody targeting interferon beta (IFN-beta) provided substantial reductions in the skin lesions associated with dermatomyositis in a double-blind, placebo-controlled phase ...

Ilona Szer, MD, [16] Clinical Professor of Pediatrics and Rheumatology at Children's Hospital San Diego, presented a subset of rheumatologic diseases seen frequently in the dermatology clinic due to ...

Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDTCompany ParticipantsMatthew Gline - ...